Work

Abstract CT141: A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumors

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2021-ct141

Authors: Omid Hamid, Jason Luke, Alexander Spira, Geoffrey M. Kuesters, Iga Sienczylo, Gilad Gordon, Melissa L. Johnson

Institutions: Angeles Clinic and Research Institute, University of Pittsburgh, Virginia Cancer Specialists, Rubius Therapeutics (United States), Tennessee Oncology

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3178719583

Cites:

Cited by: 2

Related to: 10